INSM stock news · Insmed
Get alerts for INSM
Follow Insmed (INSM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for INSMAnalysts at Renta 4 Banco looked into how Sanofi buying Insmed could fit with its plans.
NeutralSanofi is exploring a possible purchase of Insmed, but no offer has been made. The report gives no offer terms or confirmed deal, so it does not change Insmed's outlook.
Sanofi is looking at buying Insmed, which has caused Insmed's stock price to jump.
Good for INSMReports say Sanofi is evaluating a possible takeover of Insmed, raising the chance of a buyer. The report is unconfirmed and gives no agreed price, but the takeover interest favors Insmed.
Sanofi is looking into buying Insmed as part of its growth plans.
NeutralInsmed is named as a possible takeover target, but no offer or agreement is reported. That leaves no confirmed change to Insmed's business outlook.
Insmed Inc. is changing its directors and officers, adding Paul Hudson and Utpal Koppikar to the board.
NeutralInsmed added 2 experienced biopharma leaders to its board. Their backgrounds may help oversight, but the filing reports no business change and adds director pay and stock awards, leaving the outlook unchanged.
Insmed shares the details from its earnings call for the second quarter of 2026.
Good for INSMInsmed reported $309 million in Brensocatib sales, up 49% from the prior quarter, and raised its 2026 sales forecast, pointing to a stronger outlook.